Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 51, 2010, Pages 21990-21995

  Choi, Jung Suk ^a   Braymer, Joseph J ^a   Nanga, Ravi P R ^a   Ramamoorthy, Ayyalusamy ^a   Lim, Mi Hee ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amyloid peptide; Copper; Rational structure based design; Reactive oxygen species; Zinc

Indexed keywords

AMYLOID BETA PROTEIN; METAL ION; N (PYRIDIN-2 YLMETHYL)ANILINE; N1,N1 DIMETHYL N4 (PYRIDIN 2 YLMETHYL)BENZENE 1,4 DIAMINE; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN HOMOGENATE; BRAIN TISSUE; CHEMICAL INTERACTION; CONFORMATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METAL BINDING; NEUROBLASTOMA CELL; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIGNAL TRANSDUCTION; SPECTROSCOPY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELL LINE, TUMOR; COPPER; HUMANS; PHENYLENEDIAMINES; PYRIDINES; ZINC;

EID: 78650669293     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1006091107     Document Type: Article

References (53)

1. Jakob-Roetne R, Jacobsen H (2009) Alzheimer's disease: From pathology to therapeutic approaches. Angew Chem Int Ed 48:3030-3059.
2. Scott LE, Orvig C (2009) Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev 109:4885-4910.
3. Gaggelli E, Kozlowski H, Valensin D, Valensin G (2006) Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 106:1995-2044.
4. Rauk A (2009) The chemistry of Alzheimer's disease. Chem Soc Rev 38:2698-2715.
5. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8:101-112.
6. Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5:421-432.
7. Barnham KJ, Curtain CC, Bush AI (2007) Part B: Molecular mechanisms of conformational diseases. Protein Misfolding, Aggregation and Conformational Diseases, eds VN Uversky and A Fink (Springer Science+Business, Media, NY), pp 31-47.
8. Faller P, Hureau C (2009) Bioinorganic chemistry of copper and zincions coordinated to amyloid-β peptide. Dalton Trans 1080-1094.
9. Faller P (2009) Copper and zinc binding to amyloid-β: Coordination, dynamics, aggregation, reactivity and metal-ion transfer. ChemBioChem 10:2837-2845.
10. Zatta P, Drago D, Bolognin S, Sensi SL (2009) Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 30:346-355.
11. Zhu X, Su B, WangX, Smith MA, Perry G (2007) Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 64:2202-2210. (Pubitemid 47347959)
12. Hureau C, Faller P (2009)Aβ-mediated ROS production byCu ions: Structural insights, mechanisms and relevance to Alzheimer's disease. Biochimie 91:1212-1217.
13. Perez LR, Franz KJ (2010) Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease. Dalton Trans 2177-2187.
14. Cherny RA, et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
15. Faux NG, et al. (2010) PBT2 rapidly improves cognition in Alzheimer's disease: Additional phase II analyses. J Alzheimers Dis 20:509-516.
16. Chen T, et al. (2009) Effects of cyclen and cyclam on zinc(II)- and copper(II)-induced amyloid β-peptide aggregation and neurotoxicity. Inorg Chem 48:5801-5809.
17. Mancino AM, Hindo SS, Kochi A, Lim MH (2009) Effects of clioquinol on metaltriggered amyloid-β aggregation revisited. Inorg Chem 48:9596-9598.
18. Arbiser JL, et al. (1998) Clioquinol-zinc chelate: A candidate causative agent of subacute myelo-optic neuropathy. Mol Med 4:665-670.
19. Dedeoglu A, et al. (2004) Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 39:1641-1649.
20. Wu W-h, et al. (2008) Sequestration of copper from β-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. J Biol Chem 283:31657-31664.
21. Rodríguez-Rodríguez C, et al. (2009) Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. J Am Chem Soc 131:1436-1451.
22. Hindo SS, et al. (2009) Small molecule modulators of copper-induced Aβ aggregation. J Am Chem Soc 131:16663-16665.
23. Hureau C, Sasaki I, Gras E, Faller P (2010) Two functions, one molecule: A metal-binding and a targeting moiety to combat Alzheimer's disease. ChemBioChem 11:950-953.
24. Braymer JJ, DeToma AS, Choi J-S, Ko KS, Lim MH (2011) Recent development of bifunctional small molecules to study metal-amyloid-β species in Alzheimer's disease. Int J Alzheimers Dis doi:10.4061/2011/623051.
25. Clark DE, Pickett SD (2000) Computational methods for the prediction of 'druglikeness'. Drug Discov Today 5:49-58.
26. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26. (Pubitemid 33653411)
27. Kung HF, et al. (2001) Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 123:12740-12741.
28. Bloom SM, Borror AL, Greenwald RB (1975) Precursors of β-aza-disubstituted amino styryl dyes. US Patent 4, 006, 151.
29. Zhuang Z-P, et al. (2003) Structure-activity relationship of imidazo[1, 2-a]pyridines as ligands for detecting β-amyloid plaques in the brain. J Med Chem 46:237-243.
30. Leuma Yona R, Mazères S, Faller P, Gras E (2008) Thioflavin derivatives as markers for amyloid-β fibrils: Insights into structural features important for high-affinity binding. ChemMedChem 3:63-66.
31. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT (2003) High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38:223-232.
32. pION Inc. (2009)BBB protocol and testcompounds. Report (pION Inc., Woburn, MA).
33. Martell AE, Smith RM (1974-1989) Critical Stability Constants (Plenum, New York).
34. Baes CF, Jr, Mesmer RE (1986) The Hydrolysis of Cations (Krieger Publishing Co, Malabar, FL).
35. Storr T, et al. (2007) Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy. J Am Chem Soc 129:7453-7463.
36. Danielsson J, Pierattelli R, Banci L, Gräslund A (2007) High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid β-peptide. FEBS J 274:46-59.
37. Hou L, Zagorski MG(2006)NMR reveals anomalous copper (II) binding to the amyloid Aβ peptide of Alzheimer's disease. J Am Chem Soc 128:9260-9261.
38. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ (1998) Solution structure of amyloid β-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think itis? Biochemistry 37:11064-11077.
39. Jarvet J, Danielsson J, Damberg P, Oleszczuk M, Gräslund A (2007) Positioning of the Alzheimer Aβ(1-40) peptide in SDS micelles using NMR and paramagnetic probes. J Biomol NMR 39:63-72.
40. Shao H, Jao S, Ma K, Zagorski MG (1999) Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimer's disease. J Mol Biol 285:755-773.
41. Mandal PK, Pettegrew JW (2008) Aβ peptide interactions with isoflurane, propofol, thiopental and combined thiopental with halothane: A NMR study. Biochim Biophys Acta 1778:2633-2639.
42. Wahlström A, Hugonin L, Perélvarez-Marín A, Jarvet J, Gräslund A (2008) Secondary structure conversions of Alzheimer'sAβ(1- 40) peptide induced by membrane-mimicking detergents. FEBSJ 275:5117-5128.
43. Shankar GM, et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842.
44. Jarvet J, et al. (2003) A left-handed 3, helical conformation in the Alzheimer Aβ(12-28) peptide. FEBS Lett 555:371-374.
45. Butterfield SM, Lashuel HA (2010) Amyloidogenic protein-membrane interactions: Mechanistic insight from model systems. Angew Chem Int Ed 49:5628-5654.
46. Walsh DM, et al. (1999) Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945-25952.
47. Kirkitadze MD, Condron MM, Teplow DB (2001) Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J Mol Biol 312:1103-1119.
48. Himes RA, Park GY, Siluvai GS, Blackburn NJ, Karlin KD (2008) Structural studies of copper(I) complexes of amyloid-β peptide fragments: Formation of two-coordinate bis(histidine) complexes. Angew Chem Int Ed 47:9084-9087.
49. Inbar P, Bautista MR, Takayama SA, Yang J (2008) Assay to screen for molecules that associate with Alzheimer's related β-amyloid fibrils. Anal Chem 80:3502-3506.
50. LeVine H, III (1999) Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274-284.
51. Morris GM, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30:2785-2791.
52. Morris GM, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662.
53. Bolmont T, et al. (2007) Induction of tau pathology by intracerebral infusion of amyloid-β-containing brain extract and by amyloid-β deposition in APP x tau transgenic mice. Am J Pathol 171:2012-2020.